Testicular Dysfunction

Osteoporosis in Men

Volumn , Issue , 2010, Pages 423-434

  Meier, Christian ^a   Seibel, Markus J ^b   Handelsman, David J ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 81455136476     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374602-3.00035-3     Document Type: Chapter

References (117)

1. Handelsman D.J. Androgen physiology, pharmacology and abuse. Endocrinology 2009, Elsevier Saunders, Philadelphia. L.J. de Groot (Ed.).
2. Vanderschueren D., Vandenput L., Boonen S., Lindberg M.K., Bouillon R., Ohlsson C. Androgens and bone. Endocr Rev. 2004, 25(3):389-425.
3. de Ronde W., Pols H.A., van Leeuwen J.P., de Jong F.H. The importance of oestrogens in males. Clin. Endocrinol (Oxf) 2003, 58(5):529-542.
4. Khosla S., Melton L.J., Riggs B.L. Clinical review 144: estrogen and the male skeleton. J. Clin. Endocrinol. Metab. 2002, 87(4):1443-1450.
5. Callewaert F., Venken K., Ophoff J., et al. Differential regulation of bone and body composition in male mice with combined inactivation of androgen and estrogen receptor-alpha. Faseb J. 2009, 23(1):232-240.
6. Sartorius G., Handelsman D.J. Testicular, dysfunction in systemic diseases. Andrology: Male Reproductive Health and Dysfunction 2009, Springer-Verlag, Berlin. third edn. E. Nieschlag, H.M. Behre (Eds.).
7. Taieb J., Mathian B., Millot F., et al. Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clin. Chem. 2003, 49(8):1381-1395.
8. Sikaris K., McLachlan R.I., Kazlauskas R., de Kretser D., Holden C.A., Handelsman D.J. Reproductive hormone reference intervals for healthy fertile young men: evaluation of automated platform assays. J. Clin. Endocrinol. Metab. 2005, 90(11):5928-5936.
9. Ly L.P., Handelsman D.J. Empirical estimation of free testosterone from testosterone and sex hormone-binding globulin immunoassays. Eur. J. Endocrinol. 2005, 152(3):471-478.
10. Belanger A., Candas B., Dupont A., et al. Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. J. Clin. Endocrinol. Metab. 1994, 79(4):1086-1090.
11. Orwoll E., Lambert L.C., Marshall L.M., et al. Testosterone and estradiol among older men. J. Clin. Endocrinol. Metab. 2006, 91(4):1336-1344.
12. Liu P.Y., Beilin J., Meier C., et al. Age-related changes in serum testosterone and sex hormone binding globulin in Australian men: longitudinal analyses of two geographically separate regional cohorts. J. Clin. Endocrinol. Metab. 2007, 92(9):3599-3603.
13. Testosterone and Aging: Clinical Research Directions. 2003, National Academies Press, Washington DC. C.T. Liverman, D.G. Blazer (Eds.).
14. Kaufman J.M., Vermeulen A. Declining gonadal function in elderly men. Bailliéres Clin. Endocrinol. Metab. 1997, 11(2):289-309.
15. Harman S.M., Metter E.J., Tobin J.D., Pearson J., Blackman M.R. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J. Clin. Endocrinol. Metab. 2001, 86(2):724-731.
16. Feldman H.A., Longcope C., Derby C.A., et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J. Clin. Endocrinol. Metab. 2002, 87(2):589-598.
17. Liu P.Y., Death A.K., Handelsman D.J. Androgens and cardiovascular disease. Endocr. Rev. 2003, 24(3):313-340.
18. G. Sartorius, L.P. Ly, K. Sikaris, R.I. McLachlan, D.J. Handelsman, Predictive accuracy and sources of variability in calculated free testosterone estimates, Ann. Clin. Biochem. (2009) in press.
19. Liu P.Y., Swerdloff R.S., Veldhuis J. The rationale, efficacy and safety of androgen therapy in older men: Future research and current practice recommendations. J. Clin. Endocrinol. Metab. 2004, 89(10):4789-4796.
20. Kaufman J.M., Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr. Rev. 2005, 26(6):833-876.
21. Vermeulen A., Kaufman J.M., Goemaere S., van Pottelberg I. Estradiol in elderly men. Aging. Male. 2002, 5(2):98-102.
22. Khosla S., Melton L.J., Atkinson E.J., O'Fallon W.M., Klee G.G., Riggs B.L. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J. Clin. Endocrinol. Metab. 1998, 83(7):2266-2274.
23. Hsing A.W., Stanczyk F.Z., Belanger A., et al. Reproducibility of serum sex steroid assays in men by RIA and mass spectrometry. Cancer Epidemiol. Biomarkers Prev. 2007, 16(5):1004-1008.
24. Gilsanz V., Gibbens D.T., Roe T.F., et al. Vertebral bone density in children: effect of puberty. Radiology 1988, 166(3):847-850.
25. Lu P.W., Briody J.N., Ogle G.D., et al. Bone mineral density of total body, spine, and femoral neck in children and young adults: a cross-sectional and longitudinal study. J. Bone Miner Res. 1994, 9(9):1451-1458.
26. Theintz G., Buchs B., Rizzoli R., et al. Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects. J. Clin. Endocrinol. Metab. 1992, 75(4):1060-1065.
27. Misra M., Klibanski A. Anorexia nervosa and osteoporosis. Rev. Endocr. Metab. Disord. 2006, 7(1-2):91-99.
28. Seeman E. Invited review: pathogenesis of osteoporosis. J. Appl. Physiol. 2003, 95(5):2142-2151.
29. Seeman E. Pathogenesis of bone fragility in women and men. Lancet 2002, 359(9320):1841-1850.
30. Bonjour J.P., Theintz G., Buchs B., Slosman D., Rizzoli R. Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. J. Clin. Endocrinol. Metab. 1991, 73(3):555-563.
31. Riis B.J., Krabbe S., Christiansen C., Catherwood B.D., Deftos L.J. Bone turnover in male puberty: a longitudinal study. Calcif. Tissue Int. 1985, 37(3):213-217.
32. Parker L.N. Adrenarche. Endocrinol Metab. Clin. North Am. 1991, 20(1):71-83.
33. Shaw N.J. Management of osteoporosis in children. Eur. J. Endocrinol. 2008, 159(Suppl. 1):S33-S39.
34. Soule S.G., Conway G., Prelevic G.M., Prentice M., Ginsburg J., Jacobs H.S. Osteopenia as a feature of the androgen insensitivity syndrome. Clin. Endocrinol. (Oxf). 1995, 43(6):671-675.
35. Finkelstein J.S., Klibanski A., Neer R.M., Greenspan S.L., Rosenthal D.I., Crowley W.F. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann. Intern. Med. 1987, 106(3):354-361.
36. Finkelstein J.S., Klibanski A., Neer R.M., et al. Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J. Clin. Endocrinol. Metab. 1989, 69(4):776-783.
37. Arisaka O., Arisaka M., Hosaka A., Shimura N., Yabuta K. Effect of testosterone on radial bone mineral density in adolescent male hypogonadism. Acta. Paediatr. Scand. 1991, 80(3):378-380.
38. Devogelaer J.P., De Cooman S., Nagant de Deuxchaisnes C. Low bone mass in hypogonadal males. Effect of testosterone substitution therapy, a densitometric study. Maturitas 1992, 15(1):17-23.
39. Naftolin F. Brain aromatization of androgens. J. Reprod. Med. 1994, 39(4):257-261.
40. Smith E.P., Boyd J., Frank G.R., et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N. Engl. J. Med. 1994, 331(16):1056-1061.
41. Morishima A., Grumbach M.M., Simpson E.R., Fisher C., Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J. Clin. Endocrinol. Metab. 1995, 80(12):3689-3698.
42. Carani C., Qin K., Simoni M., et al. Effect of testosterone and estradiol in a man with aromatase deficiency. N. Engl. J. Med. 1997, 337(2):91-95.
43. Maffei L., Murata Y., Rochira V., et al. Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. J. Clin. Endocrinol. Metab. 2004, 89(1):61-70.
44. Falahati-Nini A., Riggs B.L., Atkinson E.J., O'Fallon W.M., Eastell R., Khosla S. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J. Clin. Invest. 2000, 106(12):1553-1560.
45. Leder B.Z., LeBlanc K.M., Schoenfeld D.A., Eastell R., Finkelstein J.S. Differential effects of androgens and estrogens on bone turnover in normal men. J. Clin. Endocrinol. Metab. 2003, 88(1):204-210.
46. Bilezikian J.P. Osteoporosis in men. J. Clin. Endocrinol. Metab. 1999, 84(10):3431-3434.
47. Leder B.Z., Finkelstein J.S. Gonadal steroids and the skeleton in men. Contemporary Endocrinology. Osteoporosis. Pathophysiology and Clinical Management 2003, 393-411. Humana Press, Totowa, New Jersey. E.S. Orwoll, M. Bliziotes (Eds.).
48. Stepan J.J., Lachman M., Zverina J., Pacovsky V., Baylink D.J. Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J. Clin. Endocrinol. Metab. 1989, 69(3):523-527.
49. Goldray D., Weisman Y., Jaccard N., Merdler C., Chen J., Matzkin H. Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH). J. Clin. Endocrinol. Metab. 1993, 76(2):288-290.
50. Smith M.R., McGovern F.J., Zietman A.L., et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 2001, 345(13):948-955.
51. Stoch S.A., Parker R.A., Chen L., et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J. Clin. Endocrinol. Metab. 2001, 86(6):2787-2791.
52. Diamond T., Campbell J., Bryant C., Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 1998, 83(8):1561-1566.
53. Basaria S., Lieb J., Tang A.M., et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin. Endocrinol. (Oxf). 2002, 56(6):779-786.
54. Mittan D., Lee S., Miller E., Perez R.C., Basler J.W., Bruder J.M. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J. Clin. Endocrinol. Metab. 2002, 87(8):3656-3661.
55. Wei J.T., Gross M., Jaffe C.A., et al. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology 1999, 54(4):607-611.
56. Berruti A., Dogliotti L., Gorzegno G., et al. Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin. Chem. 1999, 45(8 Pt 1):1240-1247.
57. Daniell H.W. Osteoporosis after orchiectomy for prostate cancer. J. Urol. 1997, 157(2):439-444.
58. Kiratli B.J., Srinivas S., Perkash I., Terris M.K. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 2001, 57(1):127-132.
59. Townsend M.F., Sanders W.H., Northway R.O., Graham S.D. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 1997, 79(3):545-550.
60. Hatano T., Oishi Y., Furuta A., Iwamuro S., Tashiro K. Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int. 2000, 86(4):449-452.
61. Oefelein M.G., Ricchuiti V., Conrad W., et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J. Urol. 2001, 166(5):1724-1728.
62. Melton L.J., Alothman K.I., Khosla S., Achenbach S.J., Oberg A.L., Zincke H. Fracture risk following bilateral orchiectomy. J. Urol. 2003, 169(5):1747-1750.
63. Smith M.R., Fallon M.A., Lee H., Finkelstein J.S. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J. Clin. Endocrinol. Metab. 2004, 89(8):3841-3846.
64. Lopez A.M., Pena M.A., Hernandez R., Val F., Martin B., Riancho J.A. Fracture risk in patients with prostate cancer on androgen deprivation therapy. Osteoporos Int. 2005, 16(6):707-711.
65. Shahinian V.B., Kuo Y.F., Freeman J.L., Goodwin J.S. Risk of fracture after androgen deprivation for prostate cancer. N. Engl. J. Med. 2005, 352(2):154-164.
66. Diamond T.H., Higano C.S., Smith M.R., Guise T.A., Singer F.R. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 2004, 100(5):892-899.
67. Francis R.M. The effects of testosterone on osteoporosis in men. Clin. Endocrinol. (Oxf). 1999, 50(4):411-414.
68. Smith D.A., Walker M.S. Changes in plasma steroids and bone density in Klinefelter's syndrome. Calcif Tissue Res. 1977, 22(Suppl):225-228.
69. Foresta C., Ruzza G., Mioni R., Meneghello A., Baccichetti C. Testosterone, and bone loss in Klinefelter syndrome. Horm Metab Res. 1983, 15(1):56-57.
70. Horowitz M., Wishart J.M., O'Loughlin P.D., Morris H.A., Need A.G., Nordin B.E. Osteoporosis and Klinefelter's syndrome. Clin. Endocrinol. (Oxf). 1992, 36(1):113-118.
71. Greenspan S.L., Neer R.M., Ridgway E.C., Klibanski A. Osteoporosis in men with hyperprolactinemic hypogonadism. Ann. Intern. Med. 1986, 104(6):777-782.
72. Luisetto G., Mastrogiacomo I., Bonanni G., et al. Bone mass and mineral metabolism in Klinefelter's syndrome. Osteoporos Int. 1995, 5(6):455-461.
73. Bojesen A., Juul S., Gravholt C.H. Prenatal and postnatal prevalence of Klinefelter syndrome: a national registry study. J. Clin. Endocrinol. Metab. 2003, 88(2):622-626.
74. Handelsman D.J., Liu P.Y. Klinefelter's syndrome - a microcosm of male reproductive health. J. Clin. Endocrinol. Metab. 2006, 91(4):1220-1222.
75. Bojesen A., Juul S., Birkebaek N., Gravholt C.H. Increased mortality in Klinefelter syndrome. J. Clin. Endocrinol. Metab. 2004, 89(8):3830-3884.
76. Swerdlow A.J., Higgins C.D., Schoemaker M.J., Wright A.F., Jacobs P.A. Mortality in patients with Klinefelter syndrome in Britain: a cohort study. J. Clin. Endocrinol. Metab. 2005, 90(12):6516-6522.
77. Jackson J.A., Kleerekoper M., Parfitt A.M., Rao D.S., Villanueva A.R., Frame B. Bone histomorphometry in hypogonadal and eugonadal men with spinal osteoporosis. J. Clin. Endocrinol. Metab. 1987, 65(1):53-58.
78. Guo C.Y., Jones T.H., Eastell R. Treatment of isolated hypogonadotropic hypogonadism effect on bone mineral density and bone turnover. J. Clin. Endocrinol. Metab. 1997, 82(2):658-665.
79. Baran D.T., Bergfeld M.A., Teitelbaum S.L., Avioli L.V. Effect of testosterone therapy on bone formation in an osteoporotic hypogonadal male. Calcif Tissue Res. 1978, 26(2):103-106.
80. Francis R.M., Peacock M., Aaron J.E., et al. Osteoporosis in hypogonadal men: role of decreased plasma 1,25-dihydroxyvitamin D, calcium malabsorption, and low bone formation. Bone 1986, 7(4):261-268.
81. Wang C., Eyre D.R., Clark R., et al. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men - a clinical research center study. J. Clin. Endocrinol. Metab. 1996, 81(10):3654-3662.
82. Wang C., Swerdloff R.S., Iranmanesh A., et al. Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin. Endocrinol. (Oxf). 2001, 54(6):739-750.
83. Snyder P.J., Peachey H., Berlin J.A., et al. Effects of testosterone replacement in hypogonadal men. J. Clin. Endocrinol. Metab. 2000, 85(8):2670-2677.
84. Katznelson L., Finkelstein J.S., Schoenfeld D.A., Rosenthal D.I., Anderson E.J., Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J. Clin. Endocrinol. Metab. 1996, 81(12):4358-4365.
85. Morley J.E., Perry H.M., Kaiser F.E., et al. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J. Am. Geriatr. Soc. 1993, 41(2):149-152.
86. Aminorroaya A., Kelleher S., Conway A.J., Ly L.P., Handelsman D.J. Adequacy of androgen replacement influences bone density response to testosterone in androgen-deficient men. Eur. J. Endocrinol 2005, 152(6):881-886.
87. Greenspan S.L., Oppenheim D.S., Klibanski A. Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann. Intern. Med. 1989, 110(7):526-531.
88. Behre H.M., Kliesch S., Leifke E., Link T.M., Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J. Clin. Endocrinol Metab. 1997, 82(8):2386-2390.
89. Leifke E., Korner H.C., Link T.M., Behre H.M., Peters P.E., Nieschlag E. Effects of testosterone replacement therapy on cortical and trabecular bone mineral density, vertebral body area and paraspinal muscle area in hypogonadal men. Eur. J. Endocrinol. 1998, 138(1):51-58.
90. Isaia G., Mussetta M., Pecchio F., Sciolla A., di Stefano M., Molinatti G.M. Effect of testosterone on bone in hypogonadal males. Maturitas 1992, 15(1):47-51.
91. Zitzmann M., Depenbusch M., Gromoll J., Nieschlag E. X-chromosome inactivation patterns and androgen receptor functionality influence phenotype and social characteristics as well as pharmacogenetics of testosterone therapy in Klinefelter patients. J. Clin. Endocrinol. Metab. 2004, 89(12):6208-6217.
92. Khosla S., Amin S., Orwoll E. Osteoporosis in men. Endocr. Rev. 2008, 29(4):441-464.
93. Seeman E. The growth and age-related origins of bone fragility in men. Calcif Tissue Int. 2004, 75(2):100-109.
94. Wang C., Swedloff R.S., Iranmanesh A., et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. J. Clin. Endocrinol Metab. 2000, 85(8):2839-2853.
95. Wang C., Cunningham G., Dobs A., et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J. Clin. Endocrinol. Metab. 2004, 89(5):2085-2098.
96. Wang C., Swerdloff R., Kipnes M., et al. New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. J. Clin. Endocrinol. Metab. 2004, 89(8):3821-3829.
97. Schubert M., Bullmann C., Minnemann T., Reiners C., Krone W., Jockenhovel F. Osteoporosis in male hypogonadism: responses to androgen substitution differ among men with primary and secondary hypogonadism. Horm Res. 2003, 60(1):21-28.
98. Bhasin S., Storer T.W., Berman N., et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J. Clin. Endocrinol Metab 1997, 82(2):407-413.
99. Sih R., Morley J.E., Kaiser F.E., Perry H.M., Patrick P., Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J. Clin. Endocrinol. Metab. 1997, 82(6):1661-1667.
100. Szulc P., Munoz F., Claustrat B., et al. Bioavailable estradiol may be an important determinant of osteoporosis in men: the MINOS study. J. Clin. Endocrinol. Metab. 2001, 86(1):192-199.
101. Slemenda C.W., Longcope C., Zhou L., Hui S.L., Peacock M., Johnston C.C. Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens. J. Clin. Invest. 1997, 100(7):1755-1759.
102. Khosla S., Melton L.J., Atkinson E.J., O'Fallon W.M. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J. Clin. Endocrinol. Metab. 2001, 86(8):3555-3561.
103. Gennari L., Merlotti D., Martini G., et al. Longitudinal association between sex hormone levels, bone loss, and bone turnover in elderly men. J. Clin. Endocrinol. Metab. 2003, 88(11):5327-5333.
104. Riggs B.L., Khosla S., Melton L.J. Sex steroids and the construction and conservation of the adult skeleton. Endocr. Rev. 2002, 23(3):279-302.
105. Greendale G.A., Edelstein S., Barrett-Connor E. Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study. J. Bone Miner Res. 1997, 12(11):1833-1843.
106. Kenny A.M., Prestwood K.M., Marcello K.M., Raisz L.G. Determinants of bone density in healthy older men with low testosterone levels. J. Gerontol. A. Biol. Sci. Med. Sci. 2000, 55(9):M492-M497.
107. Paller C.J., Shiels M.S., Rohrmann S., et al. Relationship of sex steroid hormones with bone mineral density (BMD) in a nationally representative sample of men. Clin. Endocrinol. (Oxf). 2009, 70(1):26-34.
108. Mellstrom D., Johnell O., Ljunggren O., et al. Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden. J. Bone Miner Res. 2006, 21(4):529-535.
109. Goderie-Plomp H.W., van der Klift M., de Ronde W., Hofman A., de Jong F.H., Pols H.A. Endogenous sex hormones, sex hormone-binding globulin, and the risk of incident vertebral fractures in elderly men and women: the Rotterdam Study. J. Clin. Endocrinol. Metab. 2004, 89(7):3261-3269.
110. Amin S., Zhang Y., Felson D.T., et al. Estradiol, testosterone, and the risk for hip fractures in elderly men from the Framingham Study. Am. J. Med. 2006, 119(5):426-433.
111. Meier C., Nguyen T.V., Handelsman D.J., et al. Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study. Arch. Intern. Med. 2008, 168(1):47-54.
112. Tenover J.S. Effects of testosterone supplementation in the aging male. J. Clin. Endocrinol. Metab. 1992, 75(4):1092-1098.
113. Snyder P.J., Peachey H., Hannoush P., et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J. Clin. Endocrinol. Metab. 1999, 84(6):1966-1972.
114. Amory J.K., Watts N.B., Easley K.A., et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J. Clin. Endocrinol. Metab. 2004, 89(2):503-510.
115. Kenny A.M., Prestwood K.M., Gruman C.A., Marcello K.M., Raisz L.G. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J. Gerontol A. Biol. Sci. Med. Sci. 2001, 56(5):M266-M272.
116. Emmelot-Vonk M.H., Verhaar H.J., Nakhai Pour H.R., et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. J. Am. Med. Assoc. 2008, 299(1):39-52.
117. Bhasin S., Cunningham G.R., Hayes F.J., et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 2006, 91(6):1995-2010.